Literature DB >> 25332637

Naso-Sinusal T ALL With Aberrant Expression of CD56 Mimicking NK/T Non Hodgkin Lymphoma.

Marielle Igala1, Sofia Marouan2, Jennie Okouango Ova1, Mouna Lamchahab1, Asmae Quessar1, Said Benchekroun1.   

Abstract

T-acute lymphoblastic leukemia (T-ALL) represents 25 % of cases of acute lymphoblastic leukemia (ALL) in adults. The clinical presentation is dominated by a elevated number of white blood cells and in immunophenotype the lymphoblasts are generally Tdt positive and variably express CD1a, CD2, CD3, CD4, CD5, CD7, and CD8. NK/T non Hodgkin lymphoma is presented as a single lesion often ulcerated with torpid evolution affecting the nasal cavity, nasopharynx and/or palate. CD56 expression is while characteristic of NK-cells, and is also expressed on a subset of normal T cells. Its expression in ALL does not exclude the diagnosis and seems to be a prognostic factor of this disease. We report the case of a young woman with nasal cavity tumor which was initially diagnosed as T-cell lymphoma. This diagnosis was finally revised to conclude to T-ALL with CD56 aberrant expression.

Entities:  

Keywords:  CD56 expression; NK/T lymphoma; Naso-sinusal mass; T-acute lymphoblastic leukemia

Year:  2014        PMID: 25332637      PMCID: PMC4192152          DOI: 10.1007/s12288-014-0449-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  5 in total

1.  CD56 in T-cell acute lymphoblastic leukaemia: a malignant transformation of an early myeloid-lymphoid progenitor?

Authors:  Isabel Montero; Eduardo Rios; Ricardo Parody; Jose M Perez-Hurtado; Antonio Martin-Noya; Juan Manuel Rodriguez
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

2.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

3.  The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment.

Authors:  Leandro F F Dalmazzo; Rafael H Jácomo; André F Marinato; Lorena L Figueiredo-Pontes; Renato L G Cunha; Aglair B Garcia; Eduardo M Rego; Roberto P Falcão
Journal:  Br J Haematol       Date:  2008-11-11       Impact factor: 6.998

4.  CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Authors:  Farhad Ravandi; Jorge Cortes; Zeev Estrov; Deborah Thomas; Francis J Giles; Yang O Huh; Sherry Pierce; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian
Journal:  Leuk Res       Date:  2002-07       Impact factor: 3.156

5.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Authors:  John M Goldberg; Lewis B Silverman; Donna E Levy; Virginia Kimball Dalton; Richard D Gelber; Leslie Lehmann; Harvey J Cohen; Stephen E Sallan; Barbara L Asselin
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

  5 in total
  1 in total

Review 1.  Hematolymphoid lesions of the sinonasal tract.

Authors:  Genevieve M Crane; Amy S Duffield
Journal:  Semin Diagn Pathol       Date:  2015-09-09       Impact factor: 3.464

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.